- Home
- MI vs ANL Comparison
MI vs ANL Comparison
Compare MI & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MI | ANL |
|---|---|---|
| Founded | 2009 | 2004 |
| Country | Hong Kong | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.5M | 52.0M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | MI | ANL |
|---|---|---|
| Price | $4.00 | $1.40 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 11.3K | ★ 1.2M |
| Earning Date | 05-07-2026 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $662,718.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.57 | $0.88 |
| 52 Week High | $6.20 | $2.99 |
Technical Indicators
Market Signals| Indicator | MI | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 54.39 | 49.21 |
| Support Level | $3.95 | $1.17 |
| Resistance Level | $4.19 | $2.01 |
| Average True Range (ATR) | 0.19 | 0.22 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 46.86 | 37.64 |
Price Performance
Historical ComparisonAbout MI NFT Limited
NFT Ltd operates an online electronic platform for offering and trading artwork. Through its platform, the company allows artists/art dealers/owners to access a much bigger art trading market where artists can engage with a wide range of investors. Its platform also invests in high-end artwork accessible to ordinary people without financial resources. The company's trading platforms comprise the sale of calligraphies and paintings, jewelry, and precious stones. It generates revenue in the form of services in connection with the offering and trading of artwork on its system, consisting of listing fees, trading commissions, and management fees.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.